NUCRYST Pharmaceuticals Corp. (NUCRYST) develops, manufactures and commercializes medical products that fight infection and inflammation. The Company’s technology converts silver’s microcrystalline structure into an atomically disordered nanocrystalline coating that enhances silver’s natural antimicrobial properties. In addition, its nanocrystalline silver structures have exhibited potent anti-inflammatory properties in preclinical studies. NUCRYST produces nanocrystalline silver as a coating for wound dressing products under the trademark SILCRYST and as a powder, for use in medical devices and as an active pharmaceutical ingredient (API). NUCRYST has one wholly owned subsidiary, NUCRYST Pharmaceuticals Inc. The Company is a majority owned subsidiary of The Westaim Corporation (Westaim).